Tower Research Capital (TRC)’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.75K | Hold |
2,853
| – | – | ﹤0.01% | 4776 |
|
|
2026
Q1 | $1.43K | Sell |
2,853
-8
| -0.3% | -$5 | ﹤0.01% | 4666 |
|
|
2025
Q4 | $1.68K | Buy |
2,861
+1,415
| +98% | +$1.67K | ﹤0.01% | 4653 |
|
|
2025
Q3 | $2.73K | Buy |
1,446
+344
| +31% | +$494 | ﹤0.01% | 4588 |
|
|
2025
Q2 | $981 | Sell |
1,102
-6
| -0.5% | -$4 | ﹤0.01% | 4894 |
|
|
2025
Q1 | $576 | Buy |
1,108
+6
| +0.5% | +$4 | ﹤0.01% | 4868 |
|
|
2024
Q4 | $562 | Buy |
+1,102
| New | +$1.68K | ﹤0.01% | 5236 |
|
|
2024
Q3 | – | Sell |
-931
| Closed | -$7.35K | – | 5892 |
|
|
2024
Q2 | $7.35K | Buy |
931
+347
| +59% | +$3.15K | ﹤0.01% | 4473 |
|
|
2024
Q1 | $7.91K | Sell |
584
-214
| -27% | -$2.54K | ﹤0.01% | 4114 |
|
|
2023
Q4 | $8.62K | Sell |
798
-136
| -15% | -$1.53K | ﹤0.01% | 4487 |
|
|
2023
Q3 | $6.07K | Buy |
934
+774
| +484% | +$9.51K | ﹤0.01% | 4646 |
|
|
2023
Q2 | $2.88K | Sell |
160
-265
| -62% | -$6.18K | ﹤0.01% | 5139 |
|
|
2023
Q1 | $10K | Buy |
425
+100
| +31% | +$2.53K | ﹤0.01% | 4377 |
|
|
2022
Q4 | $8K | Sell |
325
-62
| -16% | -$2.06K | ﹤0.01% | 4427 |
|
|
2022
Q3 | $12K | Buy |
+387
| New | +$15.2K | ﹤0.01% | 4356 |
|
|
2022
Q2 | – | Sell |
-112
| Closed | -$5K | – | 6362 |
|
|
2022
Q1 | $5K | Buy |
+112
| New | +$4.12K | ﹤0.01% | 5077 |
|
|
2021
Q4 | – | Sell |
-919
| Closed | -$60K | – | 6399 |
|
|
2021
Q3 | $60K | Buy |
+919
| New | +$39.6K | ﹤0.01% | 2810 |
|
|
2021
Q2 | – | Sell |
-1,580
| Closed | -$83K | – | 5705 |
|
|
2021
Q1 | $83K | Buy |
1,580
+1,432
| +968% | +$96.1K | ﹤0.01% | 2731 |
|
|
2020
Q4 | $10K | Buy |
148
+146
| +7,300% | +$6.76K | ﹤0.01% | 4316 |
|
|
2020
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 4997 |
|
|
2020
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 4891 |
|
|
2020
Q1 | $0 | Buy |
+2
| New | +$121 | ﹤0.01% | 3581 |
|
|
2018
Q3 | – | Sell |
-111
| Closed | -$2K | – | 4073 |
|
|
2018
Q2 | $2K | Buy |
+111
| New | +$3.21K | ﹤0.01% | 3345 |
|
|
2018
Q1 | – | Sell |
-424
| Closed | -$25K | – | 3627 |
|
|
2017
Q4 | $25K | Buy |
+424
| New | +$27.3K | ﹤0.01% | 1885 |
|
|
2017
Q3 | – | Sell |
-265
| Closed | -$17.7K | – | 4024 |
|
|
2017
Q2 | $22K | Buy |
+265
| New | +$35.6K | ﹤0.01% | 1166 |
|
Other funds holding MTNB
HIW
SIG
Tower Research Capital (TRC)'s MTNB Position: Q2 2026 in Review
Tower Research Capital (TRC) held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 2,853 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4776.
Tower Research Capital (TRC) first reported a position in MTNB in Q2 2017 and has held it in 25 quarters since. The position peaked at $83K in Q1 2021. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- Tower Research Capital (TRC) held 2,853 shares of Matinas BioPharma worth $1.75K as of Q2 2026.
- Tower Research Capital (TRC) left its Matinas BioPharma share count unchanged in Q2 2026.
- Matinas BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4776 holding.
- Tower Research Capital (TRC) first reported a position in Matinas BioPharma in Q2 2017 and has held it in 25 quarters since.
- Tower Research Capital (TRC)'s Matinas BioPharma position peaked at $83K in Q1 2021.
- 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.